Redeye shares its initial comments on Kontigo Care’s Q3 2024 results, which showed slight positive d...
Tillväxtmaskinen tuffar på EQL Pharma ökade nettoomsättningen med 43,0 procent i det andra kvartalet...
Redeye provides its comment on Mendus’ Q3 2024 report.
Redeye updates its estimates and valuation following Serstech's Q3 2024 report.
Q3 sales EUR 44m (+5% y-o-y), order intake EUR 36m (-5% y-o-y) Margin improvements but slight declin...
Minor estimate changes in absolute terms Restructuring likely to carry full effect in H2'25e '25e-'2...
Redeye gives a short comment on the news that Eisai has lowered its forecast for its FY2024 (Q2-24-Q...
Redeye updates its view on Acarix following its Q3 report, showing lower revenues than anticipated.
Operatively CapMan’s Q3 fell short of our expectations mainly due to negative fair value changes, wh...
Redeye provides an initial comment on the Q3 2024 report from Serstech.
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board...
Redeye updates on G5 Entertainment post Q3-results which were weaker than expected.
Orders -9%, sales +10% vs. ABGSCe EBIT EUR 3m (vs. ABGSCe 2m), for a margin of 7% Profitability impr...
Adj. EBITA -9% vs ABG and -26% vs cons (one large outlier) 5% organic growth (ABG 8%) vs 1% in Q2 an...
Redeye updated its forecast and valuation following the Q3 report, which showed strong ARR growth (i...
